Company intelligence / Profile preview

Meletios Therapeutics

Ownership: Private
Development stage: Other

Overview

Meletios Therapeutics is developing a pipeline of broad-spectrum antiviral therapies based on its proprietary DVG platform. Its lead candidate MLT-103 has entered Phase 1 clinical trials for coronaviridae infections. Other programs targeting chikungunya fever and Zika virus are in preclinical development. The company recently received €1.2 million from Bpifrance’s Deeptech program to advance its technology toward clinical validation. No published clinical efficacy results yet.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Virus-like drug conjugateSmall molecule drug
Industry: Biotech

Partnerships

Institut Pasteur—exclusive license for DVG technology covering multiple virus families.

Beyond the preview

Go deeper on Meletios Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meletios Therapeutics.

Explore the full profile